The US FDA has approved daxibotulinumtoxinA-lanm injection (Daxxify) to temporarily improve the appearance of moderate to severe glabellar lines (frown lines) in adults.
Action: It’s an acetylcholine release inhibitor and neuromuscular blocking agent, is the first peptide-formulated, long-acting neuromodulator approved for this indication.
Adverse effects: headache (6%), eyelid ptosis (2%), and facial paresis, including facial asymmetry (1%).
Contraindicated in adults with hypersensitivity to any botulinum toxin preparation.